Combining Darolutamide with hormone therapy for high-risk prostate cancer

Medical Ethics Committee of Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University

This study is testing if combining Darolutamide with hormone therapy can shrink tumors and lower the chance of cancer coming back for men with high-risk prostate cancer before surgery.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years to 75 Years
• Sex: Male
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Nanning, Jiangsu)
• Trial ID: NCT05249712 on ClinicalTrials.gov

What this trial studies

This trial evaluates the efficacy and safety of Darolutamide in combination with Androgen-Deprivation Therapy (ADT) as a neoadjuvant treatment for patients with high-risk or very high-risk localized prostate cancer. It is a prospective, single-arm, multicenter clinical trial with a treatment cycle lasting 24 weeks. The study aims to determine if this combination can reduce tumor volume and minimize the risk of biochemical recurrence before radical prostatectomy. Participants will be closely monitored for treatment outcomes and safety throughout the trial.

Who should consider this trial

Good fit: Ideal candidates are men aged 18 to 75 with high-risk localized prostate cancer suitable for radical prostatectomy.

Not a fit: Patients with low or intermediate-risk prostate cancer or those with distant metastasis may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve surgical outcomes and reduce recurrence rates in patients with high-risk prostate cancer.

How similar studies have performed: Other studies have shown promising results with neoadjuvant therapies in prostate cancer, suggesting potential for success with this approach.

Eligibility criteria

Inclusion Criteria:

1. Patients must be ≥ 18 and ≤75 years of age；
2. All patients must have a histologically or cytologically diagnosis of prostate cancer，without distant metastasis, and suitable for radical prostatectomy；
3. All patients meet at least one of the following criteria：

   1. multi-parameter MRI or PSMA PET / CT shows clinical staging of primary tumor ≥ T3；
   2. Gleason score of primary tumor ≥ 8；
   3. prostate specific antigen (PSA) ≥20 ng/ml； d) Radiographic assessment of regional lymph node metastases (N1)；
4. Eastern Cooperative Oncology Group (ECOG) physical condition score 0- 1；
5. Patients must have adequate organ function： hematologic function：within 28 days prior to registration as evidenced by: white blood cell (WBC) ≥ 4.0 × 109 / L, platelets≥ 100 × 109 / L, hemoglobin ≥ 9 g / dL and international normalized ratio (INR) \< 1.5； renal function：within 28 days prior to registration, as evidenced by serum creatinine ≤2×ULN； hepatic function: within 28 days prior to registration, as evidenced by: total bilirubin (TBIL)≤1.5 x upper limit of normal (ULN),and SGOT (AST) and SGPT (ALT) ≤ 2.5 x ULN；
6. Patients must participate voluntarily and sign an informed consent form (ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol.
7. Patients of childbearing potential must be willing to take high-efficiency contraceptive measures during the study period and within 120 days after the last dose of treatment.

Exclusion Criteria:

1. Patients with prostate having neuroendocrine, small cell, or sarcoma-like features are not eligible.
2. Patients with low-risk and medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: multiparameter MRI or PSMA PET / CT shows clinical staging of primary tumor \< T3, Gleason score of primary tumor \< 8, and prostate specific antigen (PSA)。
3. Patients with clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases are not eligible.（any M1）。
4. Patients who have previously received androgen deprivation therapy (medical or surgical) more than 3 months or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy are not eligible
5. Patients with severe or uncontrolled concurrent infections are not eligible。
6. Patients must not have New York Heart Association Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration.
7. Patients must not have uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection.
8. Patients must not have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled.
9. The patient is mentally ill, mentally disabled or incapable of giving informed consent

Where this trial is running

Nanning, Jiangsu

• Hongqian Guo — Nanning, Jiangsu, China (Recruiting)

Study contacts

• Principal investigator: Hongqian Guo, Phd — Nanjing Drum Tower Hospital, affiliated to medical school of Nanjing University
• Study coordinator: Hongqian Guo, Phd

Conditions Prostate Cancer